Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- BMKK, AZ Join the Fray in the Domestic Diabetes Market; Will Build Their Foundation on Byetta, Bydureon
August 20, 2013
- Sandoz Gets Approval for Diovan Generics; AGs Likely to Hit Market 6 Months before Rivals
August 16, 2013
- A Record 32 Officials at Drug-related Companies Were Paid Over 100 Million Yen in FY2012; Hiroshi Mitsuhara Was Top-paid Official of a Pharmacy Chain for the 4th Year in a Row
August 16, 2013
- Swiss OKs Schizophrenia Treatment Lurasidone: DSP, Takeda
August 15, 2013
- ViiV Healthcare Wins US Regulatory Approval for Anti-HIV Drug Dolutegravir
August 15, 2013
- Generics of the Major Anticancer Drug TS-1 Launched by Just 2 Companies Due to Development Hurdles
August 15, 2013
- Eisai Paid a Total of 18.7 Billion Yen to Doctors and Medical Institutions, 1.1 Billion Yen for Research Grants
August 14, 2013
- Sitagliptin Filed for Combination Therapy with Glinides: MSD, Ono
August 14, 2013
- Novartis AG to Cease Worldwide Development of Afinitor for Hepatocellular Carcinoma
August 14, 2013
- Chugai Paid 18.1 Billion Yen to Healthcare Professionals in 2012
August 13, 2013
- Novartis’s 11-Year Research Grants to 5 Universities Total 1.1 Billion Yen
August 13, 2013
- JPWA Operating Profit Margin at 0.63%, First Gross Profit Margin Rise Since FY2007
August 13, 2013
- MSD Paid 20.8 Billion Yen to Doctors, Medical Institutions in FY2012
August 13, 2013
- Payments to Healthcare Professionals by 10 Drug Makers Top 150 Billion Yen
August 13, 2013
- Otsuka Holdings’ Pharmaceutical Sales Rise 14.8%, Global Sales for Abilify Up 21.9% in April-June Period
August 12, 2013
- Novartis Corrects Third-Party Investigation Report on Diovan Studies
August 12, 2013
- DSP to Set Up Regenerative & Cellular Medicine Office for Integrated Management of All Related Functions
August 12, 2013
- AZ’s Exenatide Promotion to Break Free from Weight-Loss Image of GLP-1 Receptor Agonists
August 9, 2013
- Ethical Drug Sales Down 0.1% in June: Crecon Report
August 9, 2013
- Seikagaku Obtains Favorable Results from PIII Study of Condoliase for Lumbar Disc Herniation, Plans to File NDA in Japan During FY2013
August 9, 2013
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…